Patents Assigned to The Kennedy Institute of Rheumatology
-
Patent number: 8383120Abstract: Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.Type: GrantFiled: January 13, 2012Date of Patent: February 26, 2013Assignee: The Mathilda and Terence Kennedy Institute of Rheumatology TrustInventors: Marc Feldmann, Ravinder N. Maini
-
Patent number: 8298537Abstract: Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.Type: GrantFiled: January 13, 2012Date of Patent: October 30, 2012Assignee: The Mathilda and Terence Kennedy Institute of Rheumatology TrustInventors: Marc Feldmann, Ravinder N. Maini
-
Patent number: 7915009Abstract: Activation of the immune response by NF-kB inducers, induction of an anergic response by NF-kB inhibitors and the inhibition and activation of immune response by the administration of an activator or inhibitor of NF-kB is disclosed. Examples of NF-kB inhibitors include IkB?, PSI, a nucleotide sequence encoding IkB? anti-sense nucleic acid encoding an NF-kB sequence, such as Rel B, and anti-NF-kB antibodies. Examples of NF-kB inducers include NIK, MEKK, IKK2, TFRRF2, and Rel B. Also disclosed are vectors encoding inducers and inhibitors of NF-kB, for example adenoviral vectors.Type: GrantFiled: December 22, 2000Date of Patent: March 29, 2011Assignee: The Mathilda and Terence Kennedy Institute of Rheumatology TrustInventors: Brian Foxwell, Marc Feldmann
-
Patent number: 7846442Abstract: Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.Type: GrantFiled: September 12, 2005Date of Patent: December 7, 2010Assignee: The Mathilda and Terence Kennedy Institute of Rheumatology TrustInventors: Marc Feldmann, Ravinder N. Maini
-
Patent number: 7838489Abstract: Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.Type: GrantFiled: October 7, 2008Date of Patent: November 23, 2010Assignee: The Mathilda and Terence Kennedy Institute of Rheumatology TrustInventors: Marc Feldmann, Ravinder Nath Maini
-
Patent number: 7651857Abstract: We describe (1) a method of enhancing antigen presentation, comprising the step of supplying to an antigen presenting cell such as a dendritic cell, or precursor cell, an inhibitor of Toll-related receptor (TRR) signalling and (2) a method of inhibiting antigen presentation, comprising the step of supplying to an antigen presenting cell such as a dendritic cell, or precursor cell, an enhancer of Toll-related receptor (TRR) signalling. The inhibitor of TRR signalling may be a dominant negative mutant of MyD88, for example MyD881pr.Type: GrantFiled: December 21, 2001Date of Patent: January 26, 2010Assignee: The Mathilda and Terence Kennedy Institute of Rheumatology TrustInventors: Brian Maurice John Foxwell, Marc Feldmann
-
Patent number: 7608262Abstract: A method of treating or preventing a cardiovascular and/or a cerebrovascular disorder in an individual is disclosed. Also disclosed is a method for treating and/or preventing a thrombotic disorder in an individual. Further disclosed is a method of decreasing plasma fibrinogen in an individual.Type: GrantFiled: February 16, 1996Date of Patent: October 27, 2009Assignee: The Kennedy Institute of RheumatologyInventors: Michael J. Elliott, Ravinder N. Maini, Marc Feldmann
-
Patent number: 7390630Abstract: A method of identifying a compound with efficacy in the treatment of chronic inflammatory disease by testing the compound for an ability to selectively inhibit the ability of Tck cells to induce pro-inflammatory cytokine release from a monocyte is disclosed. The method includes pre-incubatin Tck cells with a compound to be tested, optionally resuspending the Tck cells in the absence of the test compound, co-culturing the Tck cells with monocytes, and assaying for the production of pro-inflammatory cytokines by the monocytes. The Tck cells are produced by incubating a population of T cells with one or more cytokines or the Tck cells are isolated from synovial tissue. The Tck cells have not been contacted with an anti-CD3 antibody. The ability to selectively inhibit cytokine release indicates that the compound has efficacy in the treatment of chronic inflammatory disease.Type: GrantFiled: September 25, 2000Date of Patent: June 24, 2008Assignee: Mathilda and Terence Kennedy Institute of Rheumatology TrustInventors: Fionula Mary Brennan, Marc Feldmann, Brian Maurice John Foxwell
-
Patent number: 7070783Abstract: The present invention relates to a receptor molecule which binds to TNF comprising all or a functional portion of the extracellular domain (ECD) of two or more TNF-Rs linked via one or more polypeptide linkers. The receptor can further comprise a signal peptide of a secreted protein, such as the signal peptide of the extracellular domain of the TNF-R or the signal peptide of a cytokine. The invention also relates to isolated DNA encoding a receptor molecule which binds to TNF, comprising two or more sequences encoding all or a functional portion of the ECD of TNF-Rs linked via one or more sequences encoding a polypeptide linker. The invention further relates to a method of making a construct which expresses all or a functional portion of the ECD of two or more TNF-Rs linked via one or more polypeptide linkers and cells which express the construct.Type: GrantFiled: April 2, 1999Date of Patent: July 4, 2006Assignee: The Mathilda and Terence Kennedy Institute of RheumatologyInventors: Yuti Chernajovsky, Richard Neve, Marc Feldmann
-
Publication number: 20040228863Abstract: A method of treating and/or preventing a TNF-mediated disease in an individual is disclosed. Also disclosed is a composition comprising a tumor necrosis factor antagonist and a CD4+ T cell inhibiting agent. TNF-mediated diseases include rheumatoid arthritis; Crohn's disease, and acute and chronic immune diseases associated with transplantation.Type: ApplicationFiled: January 20, 2004Publication date: November 18, 2004Applicant: The Kennedy Institute of RheumatologyInventors: Marc Feldmann, Ravinder N. Maini, Richard O. Williams
-
Patent number: 6770279Abstract: A method for treating rheumatoid arthritis using a TNF&agr; antagonist in combination with cyclosporin or analog thereof is disclosed.Type: GrantFiled: June 8, 1998Date of Patent: August 3, 2004Assignee: The Kennedy Institute of RheumatologyInventors: Marc Feldmann, Ravinder N. Maini, Richard O. Williams
-
Publication number: 20020136723Abstract: Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.Type: ApplicationFiled: August 3, 2001Publication date: September 26, 2002Applicant: The Kennedy Institute of RheumatologyInventors: Marc Feldmann, Ravinder N. Maini
-
Patent number: 6410588Abstract: The application relates to the identification that cannabinoids, such as cannabidiol can be used to treat inflammatory diseases. Cannabinoids for use in treating inflammatory diseases, methods of treating inflammatory diseases and cannabinoids in combination with pharmaceutically acceptable carriers are claimed.Type: GrantFiled: March 6, 2001Date of Patent: June 25, 2002Assignees: The Mathilda and Terence Kennedy Institute of Rheumatology, Yissum Research and Development Company of the Hebrew University of JerusalemInventors: Marc Feldmann, Anne-Marie Malfait, Ruth Gallily, Raphael Mechoulam
-
Publication number: 20020010180Abstract: Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.Type: ApplicationFiled: January 3, 2001Publication date: January 24, 2002Applicant: The Kennedy Institute of Rheumatology, EnglandInventors: Marc Feldmann, Ravinder N. Maini
-
Patent number: 6270766Abstract: Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.Type: GrantFiled: August 1, 1996Date of Patent: August 7, 2001Assignee: The Kennedy Institute of RheumatologyInventors: Marc Feldman, Ravinder N. Maini
-
Patent number: 5958409Abstract: A method for treating multiple sclerosis, through the administration of anti-tumour necrosis factor antibody, of soluble tumour necrosis factor receptor or of a compound capable of blocking tumour necrosis factor production, its effects and/or tumour necrosis factor receptor signal transduction, is disclosed. The method can be used to aid in therapy for humans and other mammals.Type: GrantFiled: March 13, 1996Date of Patent: September 28, 1999Assignee: Kennedy Institute of RheumatologyInventors: John Leslie Turk, David Baker, Marc Feldmann
-
Patent number: 5863786Abstract: A DNA molecule is provided which encodes a polypeptide which is capable of binding human TNF.alpha. and which has the first three cysteine-rich subdomains, but not the fourth cysteine-rich subdomain, of the extracellular binding domain of a receptor selected from the 55 kD and 75 kD receptors for human TNF.alpha.. The ability of the polypeptide to bind to TNF.alpha. means that it can be used for treating diseases mediated by TNF.alpha. activity, such as rheumatoid arthritis.Type: GrantFiled: June 6, 1995Date of Patent: January 26, 1999Assignee: The Mathilda and Terence Kennedy Institute of RheumatologyInventors: Marc Feldmann, Patrick William Gray, Martin John Charles Turner, Fionula Mary Brennan
-
Patent number: 5741488Abstract: A method for treating autoimmune or inflammatory diseases, through the administration of anti-CD4 antibody in conjunction with or sequentially to anti-TNF antibody, is disclosed. The method can be used to aid in therapy for humans and other mammals with a wide variety of autoimmune or inflammatory diseases.Type: GrantFiled: May 3, 1995Date of Patent: April 21, 1998Assignee: The Kennedy Institute for RheumatologyInventors: Marc Feldman, Ravinder N. Maini, Richard O. Williams
-
Patent number: 5633145Abstract: A polypeptide is provided which is capable of binding human TNF.alpha. and which has the first three cysteine-rich subdomains, but not the fourth cysteine-rich subdomain, of the extracellular binding domain of a receptor selected from the group consisting of the 55 kD and 75 kD receptors for human TNF.alpha.. The ability of the polypeptide to bind TNF.alpha. means that it can be used for treating diseases mediated by TNF.alpha. activity, such as rheumatoid arthritis.Type: GrantFiled: May 10, 1993Date of Patent: May 27, 1997Assignee: The Mathilda and Terence Kennedy Institute of RheumatologyInventors: Marc Feldmann, Patrick W. Gray, Martin J. C. Turner, Fionula M. Brennan